Sartorius AG (FRA:SRT) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SRT Sartorius AG FRA:SRT
83 GF Score
Price €178.00
GF Value €205.10
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Sartorius AG Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:SRT
83GF Score
Sartorius AG FRA:SRT
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sartorius AG (FRA:SRT) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of €178.00 is trading 13.2% below its estimated GF Value™ of €205.10. GuruFocus considers Sartorius AG to be Modestly Undervalued.

Key valuation signals for FRA:SRT:

  • Dividends Received:
  • GF Value™: €205.10 vs. price of €178.00 (13.2% below fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the FRA:SRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
83GF Score

Get the complete analysis for FRA:SRT

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€178.00
Price
€205.10
GF Value